Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Recruiting
Phase 1
Interventional Study
Endometrial Cancer
Ovarian Cancer
Ovarian Cancer Metastatic
Ovarian Cancer Metastatic Recurrent
Non-squamous EGFR Wt NSCLC
Platinum Resistant Ovarian Cancer
PROC
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 226 (estimated)
- Sponsor
- Whitehawk Therapeutics, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Have one of the following solid tumor cancers:
1. Monotherapy escalation and backfill cohorts:
1. non-squamous EGFR-Wt NSCLC
2. Endometrial carcinoma
3. Platinum Resistant Ovarian Cancer
2. Monotherapy expansion cohorts:
1. Non-squamous EGFR-Wt NSCLC
2. Additio…
Contacts